Betty M. Tijms
A5030923361- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Bioinformatics and Genomic Networks
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Health, Environment, Cognitive Aging
- Genetic Associations and Epidemiology
- Neural dynamics and brain function
- Mental Health Research Topics
- Tryptophan and brain disorders
- Metabolomics and Mass Spectrometry Studies
- Brain Tumor Detection and Classification
- Mitochondrial Function and Pathology
- MRI in cancer diagnosis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- S100 Proteins and Annexins
- Advanced Proteomics Techniques and Applications
- Nutritional Studies and Diet
- Advanced MRI Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Folate and B Vitamins Research
- Machine Learning in Bioinformatics
- Computational Drug Discovery Methods
Amsterdam UMC Location Vrije Universiteit Amsterdam
2016-2025
Amsterdam Neuroscience
2016-2025
Amsterdam University Medical Centers
2018-2025
Vrije Universiteit Amsterdam
2018-2025
Universitat Pompeu Fabra
2022
University Medical Center
2022
University Hospital and Clinics
2022
Nia Association
2022
ID Genomics (United States)
2022
Maastricht University
2019-2021
The characterization of gray matter morphology individual brains is an important issue in neuroscience. Graph theory has been used to describe cortical morphology, with networks based on covariation volume or thickness between areas across people. Here, we extend this research by proposing a new method that describes the cortex as network. In these large-scale morphological networks, nodes represent small regions, and edges connect regions have statistically similar structure. was applied...
Grey matter atrophy is common in multiple sclerosis. However, contrast with other neurodegenerative diseases, it unclear whether grey sclerosis a diffuse 'global' process or develops, instead, according to distinct anatomical patterns. Using source-based morphometry we searched for patterns of co-varying cortical thickness and assessed their relationships white pathology, physical disability cognitive functioning. Magnetic resonance imaging was performed at 3 T 208 patients long-standing...
One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of pathology are important for health care planning clinical trial design. To estimate the prevalence abnormality persons with normal cognition, subjective cognitive decline, mild impairment, or AD dementia to examine potential implications cutoff methods,...
Abstract Alzheimer’s disease (AD), the leading cause of dementia, has an estimated heritability approximately 70% 1 . The genetic component AD been mainly assessed using genome-wide association studies, which do not capture risk contributed by rare variants 2 Here, we compared gene-based burden damaging in exome sequencing data from 32,558 individuals—16,036 cases and 16,522 controls. Next to TREM2 , SORL1 ABCA7 observed a significant rare, predicted ATP8B4 ABCA1 with risk, suggestive signal...
Abstract Alzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity critical for AD drug development. Here we define subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels individuals ( n = 419) compared to controls 187). These had alterations protein that were associated distinct processes: subtype 1 was characterized by proteins related neuronal hyperplasticity; 2 innate immune activation; 3...
Different neurodegenerative diseases can cause memory disorders and other cognitive impairments. The early detection the stratification of patients according to underlying disease are essential for an efficient approach this healthcare challenge. This emphasizes importance differential diagnostics. Most studies compare controls, or Alzheimer's with one type dementia. Such a bilateral comparison does not resemble clinical practice, where clinician is faced number different possible types Here...
Abstract BACKGROUND Low cerebrospinal fluid (CSF) amyloid-β 1–42 (Aβ 1–42) concentrations indicate amyloid plaque accumulation in the brain, a pathological hallmark of Alzheimer disease (AD). Innotest assay values Aβ have gradually increased over past 2 decades, which might lead to misclassification AD when single cutpoint for abnormality is used. We propose an unbiased approach statistically correct drift. METHODS determined year-specific cutpoints with Gaussian mixture modeling, based on...
Alzheimer's disease is biologically heterogeneous, and detailed understanding of the processes involved in patients critical for development treatments. CSF contains hundreds proteins, with concentrations reflecting ongoing (patho)physiological processes. This provides opportunity to study many biological at same time patients. We studied whether subtypes can be detected proteomics using dual clustering technique non-negative matrix factorization. In two independent cohorts (EMIF-AD MBD...
Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid and cognitive manifestation persons without dementia important for a better understanding of course AD design prevention trials.To investigate whether associated with functioning dementia.This cross-sectional study included 2908 participants normal cognition 4133 mild impairment (MCI) from 53 studies multicenter Amyloid Biomarker Study. Normal was defined as having no...
Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity key developing personalized medicine. We identified atrophy subtypes in dementia and tested whether these are already present prodromal could explain interindividual differences cognitive decline. First we retrospectively from structural MRI with data-driven cluster analysis three datasets of patients dementia: discovery data (dataset 1: n = 299, age 67 ± 8, 50% female), two independent...
Coordinated patterns of cortical morphology have been described as structural graphs and previous research has demonstrated that properties such are altered in Alzheimer's disease (AD). However, it remains unknown how these alterations related to cognitive deficits individuals, restricted group-level analysis. In the present study we investigated this question single-subject grey matter networks. This new method extracts large-scale where nodes represent small regions connected by edges when...
Purpose To investigate the diagnostic accuracy of an image-based classifier to distinguish between Alzheimer disease (AD) and behavioral variant frontotemporal dementia (bvFTD) in individual patients by using gray matter (GM) density maps computed from standard T1-weighted structural images obtained with multiple imagers independent training prediction data. Materials Methods The local institutional review board approved study. Eighty-four AD, 51 bvFTD, 94 control subjects were divided into...
Abstract Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer’s disease (AD) and considered to result from neurodegeneration. T-tau levels, however, can be increased very early stages, when neurodegeneration limited, normal advanced stages. This suggests that t-tau levels may driven by other mechanisms as well. Because pathophysiology emerging treatment target for AD, we aimed clarify molecular processes associated with CSF levels. Methods...
To investigate the influence of heterogeneity in disease progression for detecting treatment effects Alzheimer (AD) trials, using a simulation study.
Importance Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels. Objective To provide prevalence estimates of any, no more than 4, or fewer 2 CMBs association amyloid status, number, age. Design, Setting, Participants This cross-sectional study used data included the Amyloid Biomarker Study pooling initiative (January...